Detalhe da pesquisa
1.
Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.
Br J Haematol
; 204(4): 1439-1449, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37807708
2.
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Am J Hematol
; 94(1): E35-E37, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30370955
3.
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
Leukemia
; 36(1): 288-291, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34247197
4.
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.
Blood Adv
; 6(2): 368-372, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34500459